Evidence map›Paper›PMID 33743016›Full record

ArticleEuropean journal of clinical pharmacology2021

Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution.

Labib Al-Musawe, Carla Torre, Jose Pedro Guerreiro, Antonio Teixeira Rodrigues, Joao Filipe Raposo, Helder Mota-Filipe, Ana Paula Martins

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Labib Al-MusaweFaculty of Pharmacy, University of Lisbon, Lisbon, Portugal. labibalmosawy@yahoo.com.ORCID http://orcid.org/0000-0002-3330-6343
Carla TorreFaculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
Jose Pedro GuerreiroCentre for Health Evaluation & Research (CEFAR), Lisbon, Portugal.
Antonio Teixeira RodriguesCentre for Health Evaluation & Research (CEFAR), Lisbon, Portugal.
Joao Filipe RaposoNova Medical School, New University of Lisbon, Lisbon, Portugal.
Helder Mota-FilipeFaculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
Ana Paula MartinsFaculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
University of Lisbon · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe and assess the impact of polypharmacy, and its potential adverse reactions; serious clinically relevant drug-drug interactions (DDIs) and inappropriate medicines (PIMs) on glycemic target, and kidney function in a sample of older adults with type 2 diabetes (T2D).

methodsCross-sectional study was performed in a real-world database including 444 elderly people with T2D from the Portuguese Diabetes Association, aged ≥ 65 years, and registered in 2018. DDIs were analyzed using Micromedex drug-interaction platform and PIMs identified using STOPP criteria version-2.

resultsPolypharmacy was identified in 43.6% of patients. This group of patients has shown to be more females (50 vs. 39.6%, P=0.0208), higher HbA1c targets (P=0.0275), longer diabetes duration (66.4 vs. 54.4%, P=0.0019), more hypertensive (87 vs. 62.9%, P<0.0001), using more insulin (38.1 vs. 26%, P=0.0062), sulfonylureas (37.1 vs. 15.6%, P<0.0001), GLP-1 receptor-agonists (9.7 vs. 3.6%, P=0.0077), metformin-DPP-4 inhibitors (41.2 vs. 29.2%, P=0.0081), and SGLT2 inhibitors (19 vs. 9.6%, P=0.0040). A total of 8.7% of patients had potentially serious clinically relevant DDIs, mainly due to interacting medicine pairs dexamethasone and fluoroquinolones. Furthermore, 23.4% had PIMs, and cardiovascular medicines accounted for largest therapeutic group associated. Polypharmacy found to be associated with twofold greater odds of having HbA1c ≤8%, whereas PIMs associated with 2.5-fold greater odds of having HbA1c ≤9%, and 5.5-folds greater odds of having severe kidney function.

conclusionsThese findings suggested that there is a potential association between polypharmacy and PIMs and altered glycemic control, and PIMs with the deterioration of kidney function.

Indexed as

Drug InteractionsAgedAged, 80 and overAge FactorsBlood PressureBody Mass IndexComorbidityCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleGlomerular Filtration RateGlycated HemoglobinGlycemic ControlHumansHypoglycemic AgentsInappropriate PrescribingGlycated HemoglobinHypoglycemic AgentsDrug-drug interactionsElderlyGlycemic controlKidney functionPotentially inappropriate medicinesType 2 diabetes

Identifiers

PMID33743016
OpenAlexW3136723291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.